SCHEMBL624183

SCHEMBL624183

O=C(Cn1nc2ccccc2n1)N1CCN(c2cc(OCC(F)(F)F)ncn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.41
HSD17B10 Q99714 1/20 0.40
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
DCK P27707 1/20 0.38
CCR1 P32246 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CXCR3 P49682 2/20 0.37
MC4R P32245 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
CHRM2 P08172 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM5 P08912 2/20 0.37
CHRM1 P11229 2/20 0.37
CHRM3 P20309 2/20 0.37
ME2 P23368 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624215 0.84 LMNA (0.42) HSD17B10DCKKDM4ESMN1; SMN2MC4R
SCHEMBL623227 0.81 HSD17B10 (0.45) ACACBHSD17B10RAB9ASMN1; SMN2CHRM2
SCHEMBL622338 0.81 ACACB (0.43) ACACBHSD17B10DCKKDM4ESMN1; SMN2
SCHEMBL623662 0.81 SMN1; SMN2 (0.63) HSD17B10MAPTRAB9AKDM4ESMN1; SMN2
SCHEMBL624184 0.79 CXCR3 (0.47) HSD17B10CXCR3CHRM2CHRM4CHRM5
SCHEMBL622196 0.79 CYP3A4 (0.54) HSD17B10MAPTKDM4ESMN1; SMN2ALDH1A1
SCHEMBL623073 0.79 HSD17B10 (0.44) ACACBHSD17B10SMN1; SMN2CHRM2CHRM4
SCHEMBL623899 0.78 PTK2 (0.51) ACACBRAB9AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL623245 0.78 TSHR (0.53) RAB9AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL623694 0.78 RAB9A (0.42) ACACBHSD17B10MAPTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G ACACB 544/4885HSD17B10 2375/4885MAPT 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.